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Objective. Takayasu arteritis is a rare large vessel
vasculitis with incompletely understood etiology. This
study was undertaken to perform the first unbiased
genome-wide association analysis of Takayasu arteritis.
Methods. Two independent cohorts of patients
with Takayasu arteritis from Turkey and North America
were included in our study. The Turkish cohort consisted
of 559 patients and 489 controls, and the North
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American cohort consisted of 134 patients and 1,047
controls of European ancestry. Genotyping was per-
formed using the Omni1-Quad and Omni2.5 genotyping
arrays. Genotyping data were subjected to rigorous
quality control measures and subsequently analyzed to
discover genetic susceptibility loci for Takayasu arteritis.
Results. We identified genetic susceptibility loci
for Takayasu arteritis with a genome-wide level of
significance in IL6 (rs2069837) (odds ratio [OR] 2.07,
P 5 6.70 3 1029), RPS9/LILRB3 (rs11666543) (OR
1.65, P 5 2.34 3 1028), and an intergenic locus on
chromosome 21q22 (rs2836878) (OR 1.79, P 5 3.62 3
10210). The genetic susceptibility locus in RPS9/
LILRB3 lies within the leukocyte receptor complex
gene cluster on chromosome 19q13.4, and the disease
risk variant in this locus correlates with reduced
expression of multiple genes including the inhibitory
leukocyte immunoglobulin-like receptor gene LILRB3
(P 5 2.29 3 1028). In addition, we identified candidate
susceptibility genes with suggestive levels of association
(P < 1 3 1025) with Takayasu arteritis, including PCSK5,
LILRA3, PPM1G/NRBP1, and PTK2B.
Conclusion. Our findings indicate novel genetic
susceptibility loci for Takayasu arteritis and uncover
potentially important aspects of the pathophysiology of
this form of vasculitis.
Takayasu arteritis is a rare inflammatory disease
that typically involves the aorta and its major branches
(1–3). The disease causes arterial stenosis, blood-vessel
wall thickening, dilation, and progressive occlusion,
leading to potentially life-threatening ischemia, aortic
regurgitation, and absent or reduced pulses (1–3).
Takayasu arteritis can manifest with a broad range of
nonspecific symptoms, including fever, fatigue, arthral-
gia, myalgia, and weight loss, and has a typical age at
onset of between 20 and 40 years (4,5). The disease
occurs worldwide and in all ethnicities, but the highest
prevalence has been reported in East Asia, India, and
Mexico. It is much more common in women, although
the extent of this sex bias seems to be ethnicity depend-
ent (4,6).
The etiology of Takayasu arteritis remains elu-
sive. However, there is strong evidence of genetic con-
tribution to the pathogenesis of the disease, supported
by the repeatedly confirmed genetic association
with HLA–B*52 across multiple ethnicities (7–10).
Recently, the genetic association between Takayasu
arteritis and the HLA extended region was investigated
using dense genotyping and imputation analysis (11).
These data, which were derived by examining 2 sets of
patients and controls from 2 different ethnicities, estab-
lished the presence of 2 independent genetic associa-
tions within the HLA region in Takayasu arteritis (11).
The strongest genetic association is in the HLA–B/
MICA region, and the other is in the HLA–DQB1/
HLA–DRB1 locus in HLA class II. Outside the HLA
region, we have previously established the association
between Takayasu arteritis and genetic variants in
IL12B (encoding the P40 regulatory subunit of
interleukin-12 [IL-12] and IL-23 cytokines), and in the
region encoding Fcg receptors IIa and IIIa with a
genome-wide level of significance (11). The association
with the same genetic variants in IL12B was simultane-
ously described and confirmed in a Japanese cohort of
patients with Takayasu arteritis (12). In this analysis,
we performed the first unbiased genome-wide associa-
tion study (GWAS) in Takayasu arteritis in 2 ethnically
distinct cohorts of patients and controls.
PATIENTS AND METHODS
Patients and controls. We studied 2 ethnically dis-
tinct cohorts of patients with Takayasu arteritis and controls
from Turkey and North America. The Turkish cohort
included 559 patients enrolled by the Turkish Takayasu Study
Group and 489 healthy controls, and the North American
cohort included 134 European American patients enrolled in
the Vasculitis Clinical Research Consortium Longitudinal
Study of Takayasu Arteritis and 1,047 European American
controls. All patients fulfilled the American College of Rheu-
matology 1990 classification criteria for Takayasu arteritis
(13). Our sample size had ;90% power to detect a genetic
effect with an odds ratio of 1.55 and with a genome-wide sig-
nificant P value of 5 3 1028 for variants with a minor allele
frequency (MAF) of 0.35, with an estimated disease preva-
lence of 2 per million for Takayasu arteritis, using an additive
genetic model. Genotyping data from the 1,047 European
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American controls were derived from dbGaP (study accession
no. phs000187.v1.p1). The study was approved by the institu-
tional review boards and the ethics committees at all partici-
pating institutions, and written informed consent was
obtained from all study participants.
Genotyping and data analysis. Genotyping of
patients and controls was performed using the Omni1-Quad
and Omni2.5 genotyping platforms (Illumina). Genotyping
data from single-nucleotide polymorphisms (SNPs) included
on both platforms were available for evaluation in both
cohorts. After genotyping, we followed rigorous quality con-
trol measures as previously described (11,14). Briefly, samples
were excluded from the analysis based on population stratifi-
cation by principal components analysis (.4 SD), identity by
descent (IBD) (.0.4), and autosomal heterozygosity (.2 SD
around the mean). A 10-component principal components
analysis was performed using EigenStrat version 4.2 (see Sup-
plementary Figure 1, available on the Arthritis & Rheumatol-
ogy web site at http://onlinelibrary.wiley.com/doi/10.1002/art.
39035/abstract) (15), and IBD and heterozygosity analyses
were performed with Plink (16). Genotyped markers were fil-
tered for MAF (.0.01), genotype success rate (.0.9), and
Hardy-Weinberg equilibrium P value (P . 0.01 for controls;
P . 0.0001 for cases). Markers with differential missingness
between patients and controls (P , 0.05) were also excluded
from the analysis.
After applying the quality control measures detailed
above, a total of 474,442 variants were evaluated in the Turk-
ish cohort and 547,389 in the North American cohort. A total
of 516 patients and 462 controls in the Turkish cohort, and
119 patients and 993 controls in the North American cohort
were included in the final analysis. Genomic control (GC)
Figure 1. Manhattan plot showing the meta-analysis results for genotyped variants in the Turkish and North American cohorts of patients with
Takayasu arteritis. The red line represents the threshold for genome-wide level of significance (P 5 5 3 1028).
Table 1. Genome-wide association analysis results showing genetic variants outside of the HLA region that were significantly associated
(P , 5 3 1028) with Takayasu arteritis in the Turkish and North American cohorts*
Turkish cohort North American cohort Meta-analysis
Locus/variant
Minor
allele
Case
MAF
Control
MAF
OR
(95% CI) P
Case
MAF
Control
MAF
OR
(95% CI) P OR P
Q
statistic P
IL6
rs2069837 G 0.10 0.19 0.51
(0.39–0.66)
1.92 3 1027 0.03 0.09 0.32
(0.15–0.69)
2.32 3 1023 0.48 6.70 3 1029 0.274
RPS9/LILRB3
rs11666543 A 0.19 0.30 0.56
(0.45–0.69)
3.55 3 1028 0.24 0.29 0.74
(0.54–1.02)
6.27 3 1022 0.61 2.34 3 1028 0.134
21q22
rs2242944 A 0.30 0.40 0.65
(0.54–0.78)
4.98 3 1026 0.22 0.36 0.51
(0.37–0.70)
3.07 3 1025 0.61 1.93 3 1029 0.211
rs2836878 A 0.19 0.29 0.56
(0.46–0.70)
9.24 3 1028 0.17 0.27 0.55
(0.39–0.78)
7.23 3 1024 0.56 3.62 3 10210 0.912
rs2836881 T 0.19 0.29 0.57
(0.46–0.70)
1.40 3 1027 0.17 0.27 0.55
(0.39–0.78)
6.85 3 1024 0.56 5.16 3 10210 0.879
* The odds ratio (OR) for the minor allele is shown. MAF 5 minor allele frequency; 95% CI 5 95% confidence interval.
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was performed using filtered non-HLA variants with MAF .
0.02, and showed no to minimum evidence of population
stratification in our cohorts (lGCTurkish 5 1.05, lGCEA 5
1.00). Genetic association analyses were performed using a
basic allelic chi-square test with 1 degree of freedom, and the
results were given as asymptotic P values. Meta-analysis was
then performed using a fixed-effects model, and the results
were filtered to exclude SNPs with a Cochran’s Q statistic P
value of less than 0.05. Meta-analysis was performed using
Plink, and haplotype structure analysis was performed using
Haploview 4.2 (17).
Additional genetic variants up to the 1000 Genomes
Project density were imputed in the 3 non-HLA genetic loci
that were detected with a genome-wide level of association
with Takayasu arteritis. Imputation was performed using
Impute2 (18) and a combined reference panel consisting of
1,092 individuals (19). We applied a posterior probability
imputation threshold of 0.9, and filtered imputed variants
based on MAF (.1%), imputation success rate (.90% of
individuals), and Hardy-Weinberg P value (.0.0001) in con-
trols prior to analysis, as previously described (11). Adjusted
associations between SNPs were performed using conditional
logistic regression in Plink. Regional linkage disequilibrium
plots were generated using the programing language R ver-
sion 3.1.1.
Expression quantitative trait loci (eQTL) analysis.
Expression quantitative trait loci analysis was performed to
detect correlation between the presence or absence of the
risk alleles in the identified Takayasu arteritis susceptibility
loci and transcript expression levels in whole blood and lym-
phoblastoid cell lines. This was performed using the
Genotype-Tissue Expression Project (20) and Gene Expres-
sion Variation eQTL databases (21).
RESULTS
We identified 4 association peaks that passed
the level of genome-wide significance. In addition to
the association with the HLA regions (rs12524487 [OR
3.29, P 5 8.17 3 10220]), 3 genetic associations in non-
HLA loci were identified (Figure 1). We detected
genetic associations between Takayasu arteritis and IL6
(rs2069837 [OR 2.07, P 5 6.70 3 1029]), RPS9/LILRB3
(rs11666543 [OR 1.65, P 5 2.34 3 1028]), and an
intergenic locus on chromosome 21q22 that is closest
to PSMG1 (rs2836878 [OR 1.79, P5 3.623 10210])
(Table 1).
Using the imputation approach described above,
we found additional genetic variants within these loci
that are associated with the risk of Takayasu arteritis
(Figure 2) (see Supplementary Figures 2, 3, and 4 and
Supplementary Tables 1 and 2, available on the Arthri-
tis & Rheumatology web site at http://online library.
wiley.com/doi/10.1002/art.39035/abstract). There are a
total of 10 and 11 genotyped or imputed SNPs with evi-
dence of at least modest genetic association (P , 0.05)
that are in linkage disequilibrium (r2 . 0.7) with the
index SNP rs2836878 in the chromosome 21q22 region
in the Turkish and North American cohorts, respec-
tively. The high linkage disequilibrium in this locus pre-
cluded localization of this genetic effect to a single
genetic variant using conditional regression analysis.
However, the linkage disequilibrium structure in this
locus, informed by transancestral data from the Turkish
and North American cohorts, indicates that this associ-
ation in chromosome 21q22 is explained by a relatively
small region extending from 40,463,283 to 40,466,744
(HG19) located in the intergenic region between
PSMG1 and LOC101928435 (see Supplementary
Figure 2. Regional meta-analysis results for genotyped and imputed
variants in the Turkish and North American cohorts of patients with
Takayasu arteritis. Association results are shown for the IL6 (A), RPS9/
LILRB3 (B), and chromosome 21q22 (C) loci. Diamonds indicate geno-
typed variants; circles indicate imputed variants. The red line shows the
threshold for a genome-wide level of significance (P 5 5 3 1028).
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Figure 2, available on the Arthritis & Rheumatology web
site at http://onlinelibrary.wiley.com/doi/10.1002/art.
39035/abstract).
A similar approach was attempted to further
localize the novel genetic association we identified in
Takayasu arteritis in the RPS9/LILRB3 locus located
on chromosome 19q13.4. This gene-rich locus includes
multiple genes in the leukocyte immunoglobulin-like
receptor family that are known to be expressed on
antigen-presenting cells and other immunocompetent
cells and interact with HLA class I. The linkage dise-
quilibrium structure and genetic association results,
using genotyped and densely imputed genetic variants
in this region, localized the genetic effect tagged by the
index SNP in this locus (rs11666543) to a region that
includes RPS9 and LILRB3 (see Supplementary Figure
3, available on the Arthritis & Rheumatology web site
at http://onlinelibrary.wiley.com/doi/10.1002/art.39035/
abstract).
Similar to the genetic effect in chromosome
21q22, very high to complete linkage disequilibrium
precluded further localization to a single genetic vari-
ant. Since this genetic effect is in a gene-rich region, it
is possible that the functional effect of the identified
genetic variants might extend to other genes on this
same locus. Therefore, we performed eQTL analysis to
determine if the index SNP in this locus (rs11666543)
affects the expression levels of any of the genes or tran-
scripts located within 1 million base pairs upstream and
downstream of this SNP. We detected a significant
reduction in the expression of LILRB3 in lymphoblas-
toid cell lines in the presence of the risk allele (G) in
rs11666543 (P 5 2.29 3 1028) (Figure 3). The risk var-
iant in rs11666543 was also associated with significant
down-regulation of RPS9 and with up-regulation of a
long noncoding RNA (lncRNA) (CTB-83J4.1) and the
pseudogene LILRP1 in a whole blood eQTL database
(Figure 4). CTB-83J4.1 and LILRP1 are located ;16
kb and 500 kb from rs11666543, respectively. Taken
together, these data suggest that the genetic risk vari-
ant tagged by the SNP rs11666543 is a putative func-
tional variant that alters the expression of multiple
transcripts within this gene-rich region on chromosome
19q13.4.
We also identified a novel genetic association
between IL6 and Takayasu arteritis (rs2069837) (P 5
1.92 3 1027 for the Turkish cohort, P 5 2.32 3 1023
for the North American cohort, and P 5 6.70 3 1029
for the meta-analysis). This genetic variant located
within the second intron of IL6 was not in linkage
disequilibrium with any other variant that we geno-
typed or imputed in this locus. This is also consistent
with the linkage disequilibrium data in HapMap and
explains why only a single variant in this genetic locus
was identified as a risk variant for Takayasu arteritis.
We used ENCODE data to determine if this genetic
variant in IL6 localizes to a regulatory genetic region.
We found that rs2069837 in IL6 overlaps with an
Figure 3. Expression quantitative trait loci association between rs11666543 and chromosome 19q13.4 genes in lymphoblastoid cell lines. The risk
allele for Takayasu arteritis (G) was associated with a significant reduction in expression of mRNA for the leukocyte immunoglobulin-like recep-
tor gene LILRB3.
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H3K27 acetylated region, indicating that this genetic
variant is located within an active enhancer.
In addition to identifying genetic associations in
IL6, RPS9/LILRB3, and chromosome 21q22 with a
genome-wide level of significance (P , 5 3 1028), we
identified several novel genetic susceptibility loci for
Takayasu arteritis with suggestive evidence of associa-
tion with the disease (P , 1 3 1025). These include
PCSK5, ZFPM2, LOC100289420/FAM19A5, LILRA3,
SLC16A7/LOC100289417, PPM1G/NRBP1, and PTK2B
(Table 2).
Genetic association results (P , 1 3 1025) in
the 2 independent cohorts are presented in Supple-
mentary Tables 3 and 4, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.39035/abstract.
DISCUSSION
We performed the first unbiased GWAS in
Takayasu arteritis and discovered and characterized
novel genetic susceptibility loci that predispose to
Takayasu arteritis in independent cohorts from Turkey
and North America. We established 3 risk loci for the
disease outside of the HLA region with a genome-wide
level of significance (P , 5 3 1028). Two of these loci,
IL6 and RPS9/LILRB3, point to important immunore-
gulatory pathways that could further explain the under-
lying immunopathology of this large-vessel vasculitis.
The third genetic locus we established with a genome-
wide level of significance in Takayasu arteritis is
located in a region on chromosome 21q22. This same
genetic susceptibility locus confers risk for ulcerative
colitis and ankylosing spondylitis (22,23), and the risk
variant in this locus has recently been shown to
increase the expression of 2 novel lncRNA transcripts
in this intergenic region (24).
A role of IL-6 in the pathogenesis of Takayasu
arteritis has been suspected from previous studies
showing increased serum IL-6 levels in patients as com-
pared to healthy controls (25,26). IL-6 plays an impor-
tant role in regulating multiple aspects of the immune
response, including the differentiation of T cells into
Th17 cells and Treg cells (27). Previous candidate gene
association studies have suggested a modest effect of
genetic variants within the promoter region of IL6 in
Figure 4. Expression quantitative trait loci associations between rs11666543 and several transcripts in 19q13.4 in whole blood. A and B, Correla-
tion of the risk allele for Takayasu arteritis (G) in rs11666543 with increased expression of LILRP1 (A) and the long noncoding RNA CTB-
83J4.1 (B). C, Correlation of the risk allele for Takayasu arteritis (G) in rs11666543 with decreased expression of RPS9.
Table 2. Genetic variants with suggestive evidence of association with Takayasu arteritis (meta-analysis P , 1 3 1025)*
SNP Minor allele Position Gene symbol Gene location OR P Q statistic P
rs6560480 C Chr9: 78599133 PCSK5 Intron 1.49 9.34 3 1027 0.676
rs1113601 G Chr8: 106338217 ZFPM2 Intron 0.56 1.69 3 1026 0.834
rs9615754 T Chr22: 48479166 LOC100289420/FAM19A5 Intergenic 0.58 3.70 3 1026 0.195
rs410852 G Chr19: 54800371 LILRA3 Intron 1.47 3.74 3 1026 0.966
rs7956657 A Chr12: 60228857 SLC16A7/LOC100289417 Intergenic 1.67 6.13 3 1026 0.188
rs11675428 C Chr2: 27642734 PPM1G/NRBP1 Intergenic 0.54 8.06 3 1026 0.316
rs13260543 G Chr8: 27251325 PTK2B Intron 0.70 8.97 3 1026 0.156
rs7005183 G Chr8: 27260484 PTK2B Intron 0.70 9.01 3 1026 0.141
* The odds ratio (OR) for the minor allele is shown. SNP 5 single-nucleotide polymorphism.
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Takayasu arteritis (28). While our data do not show
evidence of associations with these 2 promoter region
variants (P . 0.05), we identified a novel genetic asso-
ciation in Takayasu arteritis with a genetic variant
located in a regulatory region within the second intron
of IL6. This genetic variant lies within an experimen-
tally identified active enhancer region, as suggested by
the presence of a histone H3K27 acetylation mark
within this locus and across multiple cell types. Multi-
ple case reports have suggested successful treatment of
refractory Takayasu arteritis with anti–IL-6 receptor
monoclonal antibody (tocilizumab) (29).
Our discovery of a genetic risk locus for
Takayasu arteritis on the leukocyte receptor complex
immunoregulatory gene-rich region of chromosome
19q13.4 uncovers a potentially novel aspect of this dis-
ease. This genomic region includes genes encoding for
killer cell immunoglobulin-like receptors, leukocyte imm-
unoglobulin-like receptors, and leukocyte-associated
immunoglobulin-like receptors (30). Using dense impu-
tation and transancestral mapping, we localized the
genetic susceptibility locus for Takayasu arteritis in this
region to RPS9/LILRB3.
The leukocyte immunoglobulin-like receptor
gene family encodes a set of cell surface receptor pro-
teins possessing immunoglobulin domains. Inhibitory
receptors in this gene family consist of 2 or 4 extracel-
lular immunoglobulin domains, a transmembrane
domain, and cytoplasmic immunoreceptor tyrosine-
based inhibitory motifs (ITIMs) (30). LILRB3 binds to
HLA class I antigens and generally provides a negative
inhibitory signal to limit an immune response and pre-
vent autoreactivity. Our data indicate that the index
SNP in the RPS9/LILRB3 locus tags a functional
genetic variant that regulates multiple genes within this
extended region. Specifically, the Takayasu arteritis
risk allele in rs11666543 correlates with reduced mes-
senger RNA (mRNA) expression of RPS9 and
LILRB3, and increased expression of the pseudogene
LILRP1 located ;500 kb from this SNP. In addition,
the risk allele in this locus correlates with increased
expression of an lncRNA (CTB-83J4.1) that is ;16 kb
away. These data suggest a long-range interaction
within this genomic region and a possible chromatin-
looping configuration that brings multiple genes spread
across this complex region into close proximity to this
functional regulatory locus that includes rs11666543
and that confers risk of Takayasu arteritis.
Our eQTL analysis in the chromosome 19q13.4
locus that indicates significant reduction in LILRB3
expression with the Takayasu arteritis risk allele sug-
gests loss of inhibitory signaling that could result in
enhanced uncontrolled immune activation upon major
histocompatibility complex (MHC) class I antigen pre-
sentation. It is intriguing that HLA class I is strongly
associated with the risk of Takayasu arteritis. Our study
was underpowered to establish epistatic interaction
between the HLA class I risk locus in Takayasu arteri-
tis (tagged by rs12524487 in HLA–B/MICA) and RPS9/
LILRB3 (data not shown). The variant tagging the
RPS9/LILRB3 genetic effect in Takayasu arteritis also
alters the expression of mRNA for RPS9, which enco-
des for ribosomal protein S9 and is a component of the
40S ribosomal subunit.
We previously used the ImmunoChip custom-
designed genotyping platform and found significant
genetic associations with IL12B and FCGR2A/
FCGR3A in Takayasu arteritis (14). The ImmunoChip
platform included 196,524 genetic variants and
allowed for very dense coverage and genotyping in
;200 genetic loci with a previously reported associa-
tion in immune-mediated diseases. These same var-
iants in IL12B and FCGR2A/FCGR3A were not
included in the GWAS platform used in this study
and could not be imputed and analyzed. The genetic
association results with the genotyped variants in
these 2 loci in this study are presented in Supplemen-
tary Figure 5, available on the Arthritis & Rheumatol-
ogy web site at http://onlinelibrary.wiley.com/doi/10.
1002/art.39035/abstract. Indeed, only one genetic vari-
ant analyzed in this study was in linkage disequili-
brium with the previously reported risk variant in
IL12B, and no variant was in linkage disequilibrium
with the previously reported risk variant in FCGR2A/
FCGR3A (see Supplementary Tables 5 and 6, avail-
able on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.39035/abstract).
Therefore, we predict that additional genetic suscepti-
bility loci for Takayasu arteritis will be discovered in
future studies when more comprehensive genotyping
platforms or sequencing experiments are performed.
In summary, this multiethnic first unbiased
GWAS study in Takayasu arteritis established 3 addi-
tional genetic susceptibility loci with a genome-wide
level of significance for this disease. Our study revealed
important novel aspects of the pathogenesis of Takayasu
arteritis, and brings the total number of established
genetic risk loci with a genome-wide level of significance
in this disease to 7. These are the 2 independent MHC
loci in HLA class I and class II, FCGR2A/FCGR3A,
IL12B, IL6, RPS9/LILRB3, and the intergenic locus on
chromosome 21q22 near PSMG1. Uncovering the
genetic basis for Takayasu arteritis has the great poten-
tial to lead to a better understanding of the pathogenesis
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of the disease and the discovery of novel therapeutic
targets.
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